Thank you for standing by, and welcome to the 2024 Annual Meeting of Stockholders of Intensity Therapeutics, Inc. I'd now like to turn the meeting over to Lewis H. Bender, President, Chief Executive Officer, and Chairman of the company. You may begin.
Well, thank you, Rob, and good morning. Welcome to the 2024 Annual Meeting of Stockholders of Intensity Therapeutics, Incorporated. I'm Lew Bender, President, Chief Executive Officer, and Chairman of the company, and it is my pleasure to welcome all of you. It is 10:30 A.M. Eastern Time, and in accordance with the notice of the meeting, I call to order the 2024 Annual Meeting of Stockholders of Intensity Therapeutics. We have chosen to have this meeting virtually in order to improve our stockholders' access to this meeting. It is our intention to conduct this meeting in accordance with the agenda. The agenda is currently available for review in the Meeting Materials section of the meeting website. You will note that under item 11 in the agenda, an opportunity is provided at the end of the meeting for general questions and discussion about the voting and this meeting.
Please adhere to the rules or conduct attached to your agenda in asking questions at this time. Before proceeding to the business of the meeting, I would like to introduce some people who are with us today on the webcast. First, I would like to introduce our present directors. In addition to myself, we welcome Dr. Emer Leahy, Dr. Mark Goldberg, Daniel Donovan, and Thomas Dubin. Each of Daniel Donovan and Thomas Dubin are candidates for re-election at today's meeting. Also present today are Joseph Talamo, company's Chief Financial Officer, and John Wesolowski, the company's Principal Accounting Officer and Controller, as well as Abby Macdonald from Mintz, the company's attorneys. James R. Alden of American Election Services, LLC, is here as the Inspector of Election for this meeting.
If questions arise during the discussion period that these individuals should appropriately address, they will be glad to respond. Joseph Talamo will serve as Secretary of this meeting. This meeting is held pursuant to a printed notice mailed on or about June 4th, 2024, to each stockholder of record as of May 21st, 2024. The count of shares present immediately prior to the commencement of the meeting indicated that 8,522,632 shares of the company's voting stock were present in person or by proxy. This is 62.15% of the outstanding voting stock of the company. I hereby declare a quorum present at this meeting. On behalf of the Board of Directors, I would like to express my appreciation to all stockholders who returned their proxies.
I would also like to point out that most of you who returned proxies authorized the persons named in the proxy to vote for the election of management's nominees for director. Those of you who would like to vote today may do so by clicking on the button on your screen entitled Vote Here. The first matter to be acted upon by the stockholders is the election of two directors, each to serve until the annual meeting to be held in 2027 and until his successor has been elected and qualified. I have just introduced the nominees, and additional information about them is in the Proxy Statement. I hereby declare them duly nominated. The company has not received timely notice of any other nominations. Therefore, I declare the nominations closed. If you have any questions regarding this proposal, please submit questions regarding the proposal now.
The next matter being submitted to the stockholders for action is the approval of our 2024 Employee Stock Purchase Plan. The Employee Stock Purchase Plan is summarized in the proxy statement, and the full text of the plan is attached as an appendix to the proxy statement. If you have any questions regarding the proposal, please submit questions regarding this proposal now. The last matter being submitted to stockholders for action is the ratification of the appointment of the Board of Directors of EisnerAmper LLP as auditors of Intensity Therapeutics. If you have any questions regarding this proposal, please submit questions regarding this proposal now. The stockholders who are voting at the meeting on these proposals should now vote. After voting has been completed, votes will be counted. Please vote on each proposal using the links provided in the webcast. Okay.
At this time, I hereby declare the polls closed for all proposals. We will prepare a preliminary results of the voting at this time. We have completed a preliminary count of the ballots, and a majority of the votes cast have been voted for the election of Daniel Donovan and Thomas Dubin for the terms expiring in 2027. In connection with the proposed approval of the Employee Stock Purchase Plan. 6,624,163 shares have been voted in favor. 103,613 shares have been voted against, and 7,878 shares have abstained.
Finally, in connection with the ratification of the appointment of EisnerAmper LLP to audit the financial statements of the company and its subsidiaries for fiscal year 2024, 8,516,892 shares, being more than the majority of the voting stock of the company, have been voted in favor. 4,017 shares have been voted against, and 1,723 shares have abstained. I hereby declare that Daniel Donovan and Thomas Dubin have been duly elected, that the employee stock purchase plan has been duly approved, and that the appointment of EisnerAmper LLP to audit the financial statements of the company for fiscal year 2024 has been duly ratified. After the final tabulation has been completed, it shall be placed with the minutes of this meeting.
The final results will be disclosed in a current report on Form 8-K, to be filed within four business days of this meeting. This concludes the formal portion of our meeting. I would again like to express my sincere appreciation to the stockholders who attended this meeting and voted, as well as those who submitted their proxies. The meeting is now formally adjourned. However, we are available to discuss questions which any of you may have. Please be advised that my remarks and management's responses to questions at the end of the meeting will contain some forward-looking statements. In compliance with the Private Securities Litigation Reform Act of 1995, I am advised to point out that actual results may differ significantly from results discussed in the forward-looking statements.
Factors that might cause such a difference include those set forth from time to time in the company's SEC filings, including its annual report on Form 10-K for the year ended 2023. We have now come to the part of the agenda providing for general questions and discussions about this meeting. We have not received any questions, and so the Q&A portion of the meeting is now closed. Thank you again to our stockholders.
This concludes the meeting. You may now disconnect.